CB2 receptor drug enhanced morphine pain relief while reducing morphine reward and physical dependence in mice

LY2828360 and morphine produced synergistic pain relief for chemotherapy-induced neuropathy. LY2828360 blocked morphine reward in a conditioned place preference test (via CB2 receptors) without producing reward or aversion on its own. It also partially reduced naloxone-precipitated withdrawal in morphine-dependent mice.

Isobolographic analysis of LY2828360 and morphine combinations for neuropathic pain. Conditioned place preference testing for reward in wildtype and CB2 knockout mice. Naloxone-precipitated withdrawal in morphine-dependent mice.

The opioid crisis demands alternatives that enhance pain relief while reducing addiction risk. A drug that synergizes with morphine for pain but blocks its rewarding effects could fundamentally change how opioids are used for chronic pain.

If CB2 agonists can enhance opioid pain relief while blocking reward and reducing dependence, they could transform chronic pain management by allowing effective pain control at lower opioid doses with reduced addiction risk.

Animal study using a paclitaxel neuropathic pain model. LY2828360 did not attenuate morphine tolerance in a separate pain test (hot plate). The partial nature of the withdrawal reduction suggests CB2 activation alone may not fully prevent dependence.